RFG Advisory’s Pacific Biosciences PACB Stock Holding History

RFG Advisory’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,381	Closed	-$12.9K	–	999
2025 Q2	$12.9K	Buy	+10,381	New	+$12K	﹤0.01%	919

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return

RFG Advisory's PACB Position: Q3 2025 in Review

RFG Advisory sold out of Pacific Biosciences (PACB) in Q3 2025, closing a stake of 10,381 shares — an estimated $12.9K sold.

RFG Advisory first reported a position in PACB in Q2 2025 and held it in 1 quarter. The position peaked at $12.9K in Q2 2025. 208 funds tracked by Wall St. Rank hold PACB as of Q3 2025.

RFG Advisory reported no remaining Pacific Biosciences position as of Q3 2025 after selling out during the quarter.
RFG Advisory sold 10,381 Pacific Biosciences shares in Q3 2025, an estimated $12.9K.
RFG Advisory first reported a position in Pacific Biosciences in Q2 2025 and held it in 1 quarter.
RFG Advisory's Pacific Biosciences position peaked at $12.9K in Q2 2025.
208 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2025.

Based on RFG Advisory's 13F filing for Q3 2025, filed 6 Nov 2025.